No evidence that Fluad caused Italian deaths, says EMA
This article was originally published in Scrip
The European Medicines Agency's pharmacovigilance risk assessment committee (PRAC) says there is no evidence that Novartis' flu vaccine, Fluad, caused the serious adverse events, including deaths, that led the Italian authorities to suspend two batches of the product at the end of November.
You may also be interested in...
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.